Research programme: antibody therapeutics - Lexicon/XOMA

Drug Profile

Research programme: antibody therapeutics - Lexicon/XOMA

Latest Information Update: 13 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Lexicon Pharmaceuticals; XOMA
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Metabolic disorders

Most Recent Events

  • 13 Jan 2014 Discontinued - Preclinical for Metabolic disorders in USA (unspecified route)
  • 01 Nov 2010 XOMA receives grant from under The Patient Protection and Affordable Care Act of 2010 (PPACA) for antibody development in Metabolic disorders
  • 17 Apr 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top